Taysha Gene Therapies/$TSHA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Taysha Gene Therapies
Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.
Ticker
$TSHA
Sector
Primary listing
Employees
99
Headquarters
Website
TSHA Metrics
BasicAdvanced
$1.3B
-
-$0.34
1.08
-
Price and volume
Market cap
$1.3B
Beta
1.08
52-week high
$6.02
52-week low
$1.05
Average daily volume
2.8M
Financial strength
Current ratio
12.227
Quick ratio
12.043
Long term debt to equity
27.65
Total debt to equity
28.405
Interest coverage (TTM)
-1,753.94%
Profitability
EBITDA (TTM)
-109.353
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-1,115.27%
Operating margin (TTM)
-1,130.65%
Revenue per employee (TTM)
$100,000
Management effectiveness
Return on assets (TTM)
-27.42%
Return on equity (TTM)
-68.45%
Valuation
Price to revenue (TTM)
146.231
Price to book
5.16
Price to tangible book (TTM)
5.16
Price to free cash flow (TTM)
-15.231
Free cash flow yield (TTM)
-6.57%
Free cash flow per share (TTM)
-0.293
Growth
Revenue change (TTM)
17.28%
Earnings per share change (TTM)
-4.51%
3-year revenue growth (CAGR)
57.49%
3-year earnings per share growth (CAGR)
-55.14%
What the Analysts think about TSHA
Analyst ratings (Buy, Hold, Sell) for Taysha Gene Therapies stock.
TSHA Financial Performance
Revenues and expenses
TSHA Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Taysha Gene Therapies stock?
Taysha Gene Therapies (TSHA) has a market cap of $1.3B as of April 01, 2026.
What is the P/E ratio for Taysha Gene Therapies stock?
The price to earnings (P/E) ratio for Taysha Gene Therapies (TSHA) stock is 0 as of April 01, 2026.
Does Taysha Gene Therapies stock pay dividends?
No, Taysha Gene Therapies (TSHA) stock does not pay dividends to its shareholders as of April 01, 2026.
When is the next Taysha Gene Therapies dividend payment date?
Taysha Gene Therapies (TSHA) stock does not pay dividends to its shareholders.
What is the beta indicator for Taysha Gene Therapies?
Taysha Gene Therapies (TSHA) has a beta rating of 1.08. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.